--- title: "Forget Silicon Valley's God Complex—The Real Revolution is Happening in Biotech" type: "News" locale: "en" url: "https://longbridge.com/en/news/294487137.md" description: "Tech’s obsession with biology is finally yielding commercial results, from AI-designed proteins to CRISPR therapies. But as funding pours in, the gap between scientific miracles and the brutal reality of healthcare profitability is becoming impossible to ignore." datetime: "2026-07-31T09:21:22.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/294487137.md) - [en](https://longbridge.com/en/news/294487137.md) - [zh-HK](https://longbridge.com/zh-HK/news/294487137.md) --- # Forget Silicon Valley's God Complex—The Real Revolution is Happening in Biotech I’ve watched Silicon Valley tech bros try to hack mortality for years. But let’s be clear: the actual revolution isn’t happening in a cryotherapy chamber—it’s happening in clinical-stage biotech. We are officially in the era where biology is programmable, and the money is following the science. Let’s start with the cash. If you want to see where peak hype meets actual funding, look no further than Generate Biomedicines (GENB.US). They slapped "AI" next to protein generation and easily raised USD 400 million in their early 2026 IPO. **It’s the kind of massive war chest that proves investors are still salivating over anything AI-adjacent in healthcare.** But the real heavyweights are the ones actively altering human code. CRISPR Therapeutics (CRSP.US) is no longer just a cool science experiment; it’s a commercial powerhouse. Wall Street knows it, too, with Morgan Stanley effectively doubling its price target recently. To make these advanced therapies work at scale, the industry needs superior drug design, which is exactly how AbCellera Biologics (ABCL.US) gets paid. AbCellera just banked a USD 28.1 million upfront payment in a July 2026 deal with Vertex to build next-generation T-cell engagers. Here’s the thing about any gold rush: you want to be the one selling the shovels. Twist Bioscience (TWST.US) is literally printing the synthetic DNA that fuels this entire ecosystem. Everyone needs their tools, which is why Twist Bioscience saw its Q2 2026 revenue jump 19% to USD 110.7 million—though their bottom line shows they are still burning cash to grow. Meanwhile, ImmunityBio (IBRX.US) is proving that getting a drug approved actually pays off, reporting a massive 700% revenue spike to roughly USD 113 million after rolling out its cancer therapy ANKTIVA globally. **But let’s be brutally honest.** You can engineer the most elegant cells on earth, but they still have to survive the bureaucratic mess of the US healthcare system. Just look at the hospital giant HCA Healthcare (HCA.US). Despite pulling in over USD 20.2 billion in Q2 2026 and touting new CRISPR therapies for pediatric care, HCA Healthcare is actively being squeezed by shifting Affordable Care Act policies. The science is moving at lightspeed, but the business of actual healthcare? That’s still a brutal slog. ### Related Stocks - [CRSP.US](https://longbridge.com/en/quote/CRSP.US.md) - [HCA.US](https://longbridge.com/en/quote/HCA.US.md) - [IBRX.US](https://longbridge.com/en/quote/IBRX.US.md) - [GENB.US](https://longbridge.com/en/quote/GENB.US.md) - [ABCL.US](https://longbridge.com/en/quote/ABCL.US.md) - [TWST.US](https://longbridge.com/en/quote/TWST.US.md) ## Related News & Research - [HCA Healthcare (HCA) Stock May Be 49% Undervalued As Wage Pressure Builds](https://longbridge.com/en/news/295629002.md) - [What's Going on With AbCellera Biologics Stock On Wednesday?](https://longbridge.com/en/news/295696830.md) - [NewEdge Advisors LLC Buys 3,025 Shares of HCA Healthcare, Inc. $HCA](https://longbridge.com/en/news/295636564.md) - [Twist Bioscience Director Robert Chess disposes of common shares worth $2.041.010,13](https://longbridge.com/en/news/295573422.md) - [AbCellera’s ABCL-635 Cuts Menopause Hot Flashes 83% in Phase II Trial](https://longbridge.com/en/news/295411236.md)